Cardinal Health (CAH) gains from a solid pharmaceutical segment and a diversified product portfolio. However, regulatory setbacks are a concern.

Cardinal Health's (CAH) fourth-quarter fiscal 2024 results are expected to reflect solid performance in the Pharmaceutical and Specialty Solutions...

A. O. Smith (AOS) gains from strength in its businesses, acquisitions and a solid liquidity position. However, a tough real estate market in China...

Veeva Systems' (VEEV) strong product portfolio raises optimism about the stock. However, data security threats and escalating costs are concerning.

Cardinal Health's (CAH) fourth-quarter fiscal 2024 results benefit from solid profit growth in Pharmaceutical and Specialty Solutions. The company...

While FMC faces headwinds from pricing and cost pressures, it gains on its efforts to strengthen its product portfolio and restructuring actions.

Strategic alliances and impressive product launches bode well for Thermo Fisher (TMO).

Insperity (NSP) relies on its diversified revenue base to mitigate market risks.

Bio-Rad's (BIO) robust digital PCR business and Clinical Diagnostics segments raise optimism. However, macro issues raise concerns.

Chipotle's (CMG) focus on strategic marketing and technological innovation bodes well. However, high costs are a concern.